Gilead Sciences, Inc. (GILD) stock
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$170.26+2.68 (+1.60%)
Close on Nov 17, 2026Market cap $211.18BP/E –Yield 1.86%
Gilead Sciences market cap
Market capitalization is the share price multiplied by the number of shares outstanding.
Gilead Sciences's market cap was $210.63B on Nov 11, 2026, against $156.29B a year earlier. Over the last 5 years it ranged from $74.41B to $211.81B, with a median of $104.46B.
Market Cap at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $210.63B | +38.2% |
| 2025 | Dec 31, 2025 | $152.44B | +32.5% |
| 2024 | Dec 31, 2024 | $115.09B | +13.9% |
| 2023 | Dec 29, 2023 | $101.02B | -6.2% |
| 2022 | Dec 30, 2022 | $107.66B | +18.1% |
| 2021 | Dec 31, 2021 | $91.13B | +24.8% |
| 2020 | Dec 31, 2020 | $73.00B | -11.3% |
| 2019 | Dec 31, 2019 | $82.26B | +1.6% |
| 2018 | Dec 31, 2018 | $80.94B | -13.6% |
| 2017 | Dec 29, 2017 | $93.63B | -1.1% |
| 2016 | Dec 30, 2016 | $94.67B | -35.4% |
| 2015 | Dec 31, 2015 | $146.62B | +2.8% |
| 2014 | Dec 31, 2014 | $142.67B | +23.8% |
| 2013 | Dec 31, 2013 | $115.21B | +106.9% |
| 2012 | Dec 31, 2012 | $55.67B | +79.9% |
| 2011 | Dec 30, 2011 | $30.95B | +4.7% |
| 2010 | Dec 31, 2010 | $29.55B | -24.3% |
| 2009 | Dec 31, 2009 | $39.02B | – |
See a number that looks wrong?